May 26, 2020 WebMD digital publication “Artificial intelligence and You” highlights Eyenuk innovations under the section “AI Already Transforms Medicine”. “A screening system developed by a California-based company called Eyenuk Inc. can detect diabetic retinopathy,...
Researchers from Moorfields Eye Hospital, Homerton NHS Trust, and University College London find EyeArt System to have 100% sensitivity in detecting vision-threatening retinopathy Los Angeles, CA, May 19, 2020 — Eyenuk, Inc. announced today that...
The Ophthalmology Innovation Summit (OIS) website has published an article titled, “Eyenuk’s EyeArt AI System Showing Its Value” highlighting Eyenuk’s recent success. Link to the full article on OIS.net website: Eyenuk’s EyeArt AI System Showing...
Eyenuk Invited to Present at the American Optometric Association (AOA) TeleHealth Conference as AOA Assembles Industry Leaders to Set Future Guidance for Telehealth
May 11, 2020: Amid the COVID-19 public health emergency, doctors are considering the use of telehealth-based care, as patients practice social distancing to avoid community spread. Prior to the current crisis, though, the AOA recognized...
Wagner Macula & Retina Center Adopts Novel Technology to Protect Community Eye Health During the COVID-19 Pandemic
Partnering with Eyenuk to Identify At-Risk Patients Using Telemedicine and AI VIRGINIA BEACH, VA, May 4, 2020 —Wagner Macula & Retina Center (WMRC), a leading research and treatment center specializing in diabetic retinopathy, macular degeneration,...
The EyeArt® AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada.
** In the United States, EyeArt® is limited by federal law to investigational use only and is not available for sale.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
* Claims on this page have not been evaluated by US FDA
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.